Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

Core Points - Eagle Pharmaceuticals, Inc. announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders scheduled for October 17, 2025 [1] - The company is delivering a Notice of Internet Availability of Proxy Materials to stockholders of record as of August 18, 2025 [2] - The proxy materials, including the Notice, proxy information statement, and proxy card, are accessible online [2] - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines [3] - The company's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® [3] - Eagle's pipeline includes oncology and CNS/metabolic critical care product candidates aimed at addressing underserved therapeutic areas [3]